Drug · DIN 02470349
FOQUEST
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since September 10, 2020; first marketed December 14, 2017.
- Drug Identification Number (DIN)
- 02470349
- Company (DIN owner)
- Elvium Life SciencesToronto, Ontario, Canada
- Schedule
- Controlled drugs (cdsa iii)
- Dosage form
- Capsule (Controlled-Release)
- Route
- Oral
- Therapeutic class (ATC)
- Methylphenidate N06BA04
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| METHYLPHENIDATE HYDROCHLORIDE | 85 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- August 25, 2020: NOC 24102New Drug Submission (NDS) · Change in product ownership
- December 6, 2017: NOC 20242New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “foquest”. A notice may cover another product or only some lots: read it to see what it covers.
- Purdue Pharma Foquest Capsule Product Recall (2019-07-25)July 25, 2019 · Drugs · Product safety · Type III
- Foquest Capsule (2018-08-08)August 8, 2018 · Drugs · Product safety · Type III
Other DINs named FOQUEST
- DIN 02470292 · Marketed
- DIN 02470306 · Marketed
- DIN 02470314 · Marketed
- DIN 02470322 · Marketed
- DIN 02470330 · Marketed
- DIN 02470357 · Marketed